SG

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
Shift, Research, AD, Food, Medicare, FOCUS, Narcolepsy, Doctor of Philosophy, Fibromyalgia, Prescription, New Drug Application, Agitation, Shift work, Shirin David, Physician, SG, Acquisition, Smoking, Amgen, Webcast, Somnolence, NDA, Safety, Therapy, Patient, Food and Drug Administration, Central nervous system, Eli Lilly and Company, Reboxetine, SWD, ES, MD, Migraine, Growth, Binge eating disorder, Breakthrough therapy, Total, FDA, Government, SYMPHONY, CMC, CNS, R, DSM-IV codes, Horizon Therapeutics, BED, Dextromethorphan/bupropion, NMDA, Eating disorder, Beauty salon, Video game, Pharmaceutical industry, Bank, Dietary supplement, Solriamfetol, ADHD, Medicaid

“Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.

Key Points: 
  • “Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.
  • Auvelity® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023.
  • Third quarter 2023 U.S. Sunosi total prescriptions increased by 16% versus the third quarter of 2022, and sequentially by 5% versus the second quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2023 financial results as well as to provide a corporate update.

Tecnoglass Reports Strong Third Quarter 2023 Results and Projects Double-Digit Top Line Growth in 2024

Retrieved on: 
Monday, November 6, 2023
Saint-Gobain, NYSE, International, Colombian peso, Public expenditure, SG, TGLS, Share repurchase, Conference, Organic, Internet, Environment, Growth, Webcast, Capital expenditure, Traction, Domestic, Investment, Capital, Mobile phone, Video game, Bank, Adjustment

Steady demand for our best-in-class, innovative products contributed to record single-family residential revenues, which continues to outperform despite a challenging environment.

Key Points: 
  • Steady demand for our best-in-class, innovative products contributed to record single-family residential revenues, which continues to outperform despite a challenging environment.
  • Changes in foreign currency exchange rates had an adverse impact of $0.5 million on total revenues in the quarter.
  • Excluding the impact of foreign exchange, gross margin for the third quarter of 2023 was much more in line with the second quarter of 2023 and with the expectation for full year 2023 results.
  • Upon dialing in, please request to join the Tecnoglass Third Quarter 2023 Earnings Conference Call.

Freshpet, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Adjusted gross income, Accounting, SG, EBITDA, GAAP, Internet, Growth, Capital expenditure, Depreciation, ERP, Hunting, Reinsurance, Pharmaceutical industry, Real estate, Bank, Bookkeeping, Cryptocurrency, Adjustment

SECAUCUS, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its third quarter ended September 30, 2023.

Key Points: 
  • As a result of our strong third quarter performance, we are raising our 2023 guidance today," commented Billy Cyr, Freshpet’s Chief Executive Officer.
  • Net sales increased 32.6% to $200.6 million for the third quarter of 2023 compared to $151.3 million for the third quarter of 2022.
  • Adjusted Gross Profit is a non-GAAP financial measure defined under “Non-GAAP Measures” and is reconciled to gross profit in the financial tables that accompany this release.
  • Adjusted EBITDA was $23.2 million for the third quarter of 2023, compared to $3.5 million in the prior year period.

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 3, 2023
Janus, FDA, Psoriasis, Research, JAK1, Patent, ESG, GTN, SG, Human, Acquisition, Environmental, social, and corporate governance, Biophysical environment, United States Patent and Trademark Office, Inflammation, Hair, R, Senior, Growth, Prescription, Marketing, Shanda, Webcast, SLR, New Drug Application, Scalp, PDE4, NDA, Atopic dermatitis, Patient, Dermatitis, Acceleration, Alopecia areata, Video game, Pharmaceutical industry, Security (finance), Fine chemical, Vaccine, Cosmetics

The Company anticipates further GTN improvement in the fourth quarter of 2023.

Key Points: 
  • The Company anticipates further GTN improvement in the fourth quarter of 2023.
  • In October 2023, Arcutis received FDA approval for ZORYVE for an expanded indication for the treatment of plaque psoriasis in children down to 6 years of age.
  • In September 2022, Arcutis announced positive topline results from the ARRECTOR Pivotal Phase 3 trial for the treatment of scalp and body psoriasis.
  • Arcutis management will host a conference call and webcast today at 8:30am ET to discuss the financial results for the quarter and provide a business update.

MISTRAS Provides Update on Project Phoenix

Retrieved on: 
Thursday, November 2, 2023
System, NYSE, SG, MG, Workforce, Project, Growth, Rationalization, Project Phoenix, Rare-earth element

PRINCETON JUNCTION, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, today provided an update on the status of Project Phoenix, the Company’s strategic program to increase Income from Operations through reductions in corporate administrative overhead and enhancements to pricing.

Key Points: 
  • PRINCETON JUNCTION, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, today provided an update on the status of Project Phoenix, the Company’s strategic program to increase Income from Operations through reductions in corporate administrative overhead and enhancements to pricing.
  • In February 2023, the Board of Directors announced that the Company engaged with Alix Partners to undertake an operational review designed to accelerate profitable growth by identifying meaningful margin improvement opportunities and steps to achieve sustained cost savings, referred to as Project Phoenix.
  • In addition, as part of this initiative a new commercial function was established, to drive top-line profitable revenue growth via strategic pricing and sales enablement.
  • Project Phoenix identified various opportunities, which the Company subsequently vetted through a comprehensive diligence process and has completed the validation of a majority of the initial Project Phoenix opportunities.

MISTRAS Announces Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
Process, Optimism, NYSE, International, PIN, Public expenditure, SG, MG, EBITDA, GAAP, Free cash flow, Senior, Growth, Cash flow, Data Analytics Library, Interim, Capital expenditure, Fossil fuel, Oil, Investment, Electricity generation, Administration, Workload, Health care, Reinsurance, Fine chemical, Pharmaceutical industry, Video game, Adjustment, Project Phoenix

PRINCETON JUNCTION, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a leading "one source" multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its third quarter and nine months ended September 30, 2023.

Key Points: 
  • Gross profit margin was up 210 basis points sequentially from the second quarter of 2023, driven by an improved revenue mix.
  • Selling, general and administrative expenses (“SG&A”) in the third quarter of 2023 were $39.5 million, down 3.0% compared to $40.8 million in the third quarter of 2022 and were also down 4.7% sequentially from the second quarter of 2023, as a result of the ongoing implementation of Project Phoenix.
  • Performance by certain segments during the third quarter was as follows:
    North America segment (Referred to as “Services” in prior filings) third quarter 2023 revenue was $148.8 million, down 2.6% from $152.8 million in the prior year quarter.
  • International segment third quarter 2023 revenue was $31.0 million, up 20.6% from $25.7 million in the prior year quarter inclusive of favorable foreign currency exchange.

FLINT Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
FLINT, Bank of Canada, Bank, Conversation, Pre-construction services, SG, SEDAR, Maintenance, Bank statement, Senior, Organization, Indian stock exchange, Analysis, Hand, Cryptocurrency, Security (finance), Canso

Income from continuing operations for the three months ended September 30, 2023 was $2,789 compared to $1,174 for the same period in 2022.

Key Points: 
  • Income from continuing operations for the three months ended September 30, 2023 was $2,789 compared to $1,174 for the same period in 2022.
  • As at September 30, 2023, the accrued and unpaid dividends on the Series 1 and Series 2 shares totaled $89.2 million.
  • FLINT has a suite of more than 40 service offerings that encompass the full asset lifecycle.
  • Our unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2023 and the related Management's Discussion and Analysis of the operating and financial results can be accessed on our website at www.flintcorp.com and will be available shortly through SEDAR at www.sedar.com .

AMN Healthcare Announces Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
AMN, Equifax Workforce Solutions, Public expenditure, SG, EBITDA, Share repurchase, Acquisition, MSDR, Travel, EPS, Interim, Hand, Borrowing base, Bank, Video game, Health care, Pharmaceutical industry, Nursing

DALLAS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2023 financial results. Financial highlights are as follows:

Key Points: 
  • Earnings were better than expected as in-line core results were augmented by several favorable factors that we expect will not recur in the fourth quarter.
  • “The AMN team did an impressive job balancing business execution in the third quarter alongside our initiatives to sharpen our strategic plan and implement powerful advancements in our technology platform and processes,” said Cary Grace, President and Chief Executive Officer of AMN Healthcare.
  • Adjusted diluted EPS in the third quarter was $1.97 compared with $2.57 in the same quarter a year ago.
  • Our physician and leadership search businesses saw revenue decline by 25% year over year and 10% quarter over quarter.

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Anti-transglutaminase antibodies, Research, RISE, PKU, Research and development, IND, AGIO, Rare, Sickle cell disease, MDS, Public expenditure, Enrollment, SG, Pyruvate kinase deficiency, R, Society, Phenylketonuria, ASH, Thalassemia, PK, Security, Abstract, Phenylalanine hydroxylase, TMPRSS6, Agios Pharmaceuticals, PAH, Agios, Patient, Administration, Nursing, Cryptocurrency, Pharmaceutical industry, Medical device, Video game, Alnylam Pharmaceuticals

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Launch: Generated $7.4 million in U.S. net revenue for the third quarter of 2023, a 10 percent increase over the second quarter of 2023.
  • A total of 160 unique patients have completed prescription enrollment forms, representing an increase of 9 percent over the second quarter of 2023.
  • Net Loss: Net loss was $91.3 million for the third quarter of 2023 compared to $81.7 million for the third quarter of 2022.
  • ET to discuss third quarter 2023 financial results and recent business activities.

Pacira BioSciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Research, Sale, Anesthesiology, PDUFA, Tax, PIN, Chronic pain, Bupivacaine, 340B Drug Pricing Program, SG, Telephone, Conference, GAAP, Doctor of Philosophy, Health, R, Society, Bank statement, Growth, Interest, ASA, Nerve block, Webcast, Health care, Depreciation, Conference call, Investment, American Society of Anesthesiologists, Table, Bank, Online shopping, Management, Video game, Reinsurance, Pharmaceutical industry, EBITDA, MD

TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023.

Key Points: 
  • ET --
    TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023.
  • Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.
  • Third quarter 2023 iovera° net product sales were $5.3 million, versus $4.5 million reported for the third quarter of 2022.
  • The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday, November 2, 2023, at 8:30 a.m.